We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.
- Authors
Dlouhý, Pavel; Mucha, Cyril; Mokrá, Lenka; Kuhn, Matyáš; Hrdlickova, Lenka; Arnet, Urs; Whiteside, Yohance
- Abstract
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20–99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.
- Subjects
CZECH Republic; COVID-19; MOLNUPIRAVIR; COVID-19 treatment; VACCINATION status; COVID-19 vaccines
- Publication
Journal of Clinical Medicine, 2024, Vol 13, Issue 8, p2303
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm13082303